Aerami’s upcoming merger with FoxWayne will bolster the company’s PAH portfolio
M&A Review Financial Advisor League Tables - Academic
Aerami’s upcoming merger with FoxWayne will bolster the company’s PAH portfolio
Proceeds from Aerami’s merger with FoxWayne will help advance the development of the company’s PAH therapy, AER-901 (imatinib).
Drug developer BenevolentAI enters SPAC merger deal with Odyssey
Amgen concludes acquisition of biotech company Teneobio for $2.5bn
Sanofi concludes acquisition of Translate Bio for $3.2bn
EQRx signs $1.8bn merger deal with CM Life Sciences III
AstraZeneca concludes Alexion acquisition for $39bn
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
